Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors
| Autor: | Pieter H.M. De Mulder, V. Mattijssen, Peter A. Steerenberg, Lianne T. M. Balemans |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Interleukin 2
Cancer Research Pathology medicine.medical_specialty medicine.medical_treatment Guinea Pigs Pharmacology Polyethylene Glycols chemistry.chemical_compound Tumor Cells Cultured Carcinoma medicine Animals Dose-Response Relationship Drug Epithelioma business.industry Neoplasms Experimental Immunotherapy medicine.disease Primary tumor Recombinant Proteins Cytokine Oncology chemistry Lymphatic Metastasis Axilla Systemic administration Interleukin-2 Female Lymph Nodes Growth inhibition business Neoplasm Transplantation medicine.drug |
| Zdroj: | International Journal of Cancer. 51:812-817 |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.2910510524 |
| Popis: | Polyethylene glycol-modified recombinant human interleukin-2 (PEG-IL-2) represents a cytokine with prolonged circulatory half-life and increased antitumor activity as compared to recombinant interleukin-2 (rIL-2) after systemic administration. We studied whether PEG-IL-2 would also be advantageous in locoregional immunotherapy using a syngeneic tumor model. Intradermal inoculation of line-10 tumor cells into the flanks of strain-2 guinea-pigs results in a fast-growing tumor and regional lymph-node metastases. Treatment schedules were started on day 7 after inoculation in animals with established tumors. First, groups of 5-6 animals were treated with repeated intratumoral and perilymphatic rIL-2 or PEG-IL-2 injections. PEG-IL-2 caused significant growth inhibition of both the primary tumor and the regional lymph-node metastases at lower doses and with less frequent administration than rIL-2. The best schedule for PEG-IL-2 was 3 injections a week for 5 weeks, resulting in cure of 4/17 and 5/5 (ρ < 0.01) animals at the 2 most efficient dose levels tested. Subsequent experiments indicated that the intratumoral and not the perilymphatic injection route was essential for the obtained antitumor effect. Furthermore, 12/12 animals cured after PEG-IL-2 treatment rejected a rechallenge with line-10 tumor cells, whereas no cures were seen after rIL-2 injections. PEG-IL-2 therefore appears to be a valuable substance for intratumoral immunotherapy. © 1992 Wifey-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text